Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.

Myles WolfGeoffrey A BlockGlenn M ChertowKerry CooperBruno FouqueraySharon M MoeYan SunHolly TomlinMarc G VervloetRainer Oberbauer

Published in: Clinical kidney journal (2019)

These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium.

Keyphrases

peritoneal dialysis
end stage renal disease
chronic kidney disease
electronic health record
big data